When Patents Decide Who Gets Medicine
Millions still lack access to life-saving medicines, not because science failed, but because patents, prices, and politics get in the way. This deep dive unpacks how countries have used (and sometimes avoided) TRIPS flexibilities over the past 25 years to break monopolies, enable generics, and respond to crises from HIV to COVID-19 and cancer. With rising drug prices and shrinking global health funding, these tools matter more than ever. Worth the read if access, equity, and medicine quality concern you.
Read more: https://gh.bmj.com/content/11/1/e021481